Prothena Corporation plc logo

Prothena Corporation plc

NASDAQ:PRTA

Overview | Financials
Company Name Prothena Corporation plc
Symbol PRTA
Currency USD
Price 14.16
Market Cap 761,931,192
Dividend Yield 0%
52-week-range 11.7 - 40.19
Industry Biotechnology
Sector Healthcare
CEO Dr. Gene G. Kinney Ph.D.
Website https://www.prothena.com

An error occurred while fetching data.

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal

Related Stocks

Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc.

CTKB

6.83 USD

Clover Health Investments, Corp. logo

Clover Health Investments, Corp.

CLOV

3.64 USD

Exscientia plc logo

Exscientia plc

EXAI

4.84 USD

Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc.

PACB

2.1 USD

Veracyte, Inc. logo

Veracyte, Inc.

VCYT

43.78 USD

Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc.

CLDX

26.53 USD

NextGen Healthcare, Inc. logo

NextGen Healthcare, Inc.

NXGN

23.94 USD

P3 Health Partners Inc. logo

P3 Health Partners Inc.

PIII

0.222 USD

CareDx, Inc logo

CareDx, Inc

CDNA

24 USD

Financials

Numbers are in millions USD

Numbers are in millions USD